Inmunización con vacunas ARN mensajero contra la COVID-19 en pacientes adolescentes con antecedente de síndrome inflamatorio multisistémico: serie de casos / Immunization with messenger RNA vaccines against COVID-19 in adolescents with a history of multisystem inflammatory

Los niños cursan mayormente la infección por el virus SARS-CoV-2 en forma leve. Sin embargo, de forma muy infrecuente algunos pueden desarrollar una patología con marcada gravedad denominada síndrome inflamatorio multisistémico en niños relacionado temporalmente con COVID-19 (SIM-C). Dado su reciente surgimiento, aún hay aspectos de su fisiopatología que se desconocen. La posibilidad de recidiva en caso de reinfección o ante la vacunación contra SARS-CoV-2 son nuevos interrogantes a los que nos enfrentamos. Reportamos una serie de casos de 4 pacientes adolescentes que cursaron SIM-C y meses después han sido vacunados contra SARS-CoV-2 con plataformas ARN mensajero (ARNm) sin presentar recurrencia de la enfermedad ni efectos adversos cardiológicos

In most cases, children with SARS-CoV-2 have a mild infection. However, very rarely, some children may develop a severe disease called multisystem inflammatory syndrome in children temporally associated with COVID-19 (MIS-C). Given its recent emergence, some aspects of its pathophysiology are still unknown. The possibility of recurrence in case of reinfection or SARS-CoV-2 vaccination are new questions we are facing. Here we report a case series of 4 adolescent patients who developed MIS-C and, months later, received the SARS-CoV-2 vaccine with messenger RNA (mRNA) platforms without disease recurrence or cardiac adverse events.

Association among COVID-19, multisystem inflammatory syndrome in children, and oral health status

Abstract The pathophysiology of multisystem inflammatory syndrome in children (MIS-C) and associated oral symptoms have not been clarified yet. The aim of the present study was to compare the oral health status of children with MIS-C-associated Coronavirus disease 2019 (COVID-19) and COVID-19. A total of 54 children with SARS-CoV-2 infection, 23 with MIS-C-associated COVID-19 and 31 with asymptomatic, mild, and moderate COVID-19 were recruited for the present cross-sectional study. Sociodemographic variables, medical examinations, oral hygiene habits, and extraoral and intraoral findings (DMFT/dmft index, OHI scores, and oral mucosal changes) were recorded. The t-test for independent samples and the Mann-Whitney U test were used (p < 0.05). MIS-C was found to be associated with chapped lips (all patients) and oral mucosal changes, including erythema, white lesion, strawberry tongue, and swelling of the gingiva as compared to the COVID-19 group (frequency of more than one mucosal change: 100% vs. 35%) (p < 0.001). Children with MIS-C presented higher DMFT/dmft scores (DMFT/dmft 5.52 ± 3.16 for the MIS-C group vs. 2.26 ± 1.80 for the COVID-19 group) (p < 0.01). Elevated OHI scores were also associated with MIS-C (mean ± SD: 3.06 ± 1.02 (MIS-C) vs. 2.41 ± 0.97 (COVID-19) (p < 0.05). Oral manifestations, mainly strawberry and erythematous tongue, were characteristic features of MIS-C. Prevalence of oral/dental symptoms was elevated in children with MIS-C when compared to COVID-19. Therefore, dental professionals should be aware of the oral manifestations associated with MIS-C, which may have high mortality and morbidity rates.

Rabdomiólisis severa en un lactante con síndrome inflamatorio multisistémico asociado a covid -19 (mis-c)

Introducción: un caso de rabdomiólisis severa asociado a síndrome inflamatorio multisistémico asociado a COVID -19 (MIS-C). Reporte de caso: en un niño de 1 año 10 meses que presentó síntomas digestivos, mialgias, debilidad, fiebre y orina oscura. Prueba serológica COVID-19 IgM (-) IgG (+), PCR COVID-19 negativo. Creatin-quinasa (CK) inicial fue no dosable, siendo el nivel reportado más alto de 517 600 U/L. El valor de creatinina se mantuvo normal durante toda la hospitalización. Recibió Inmunoglobulina humana 2 g/Kg, Metilprednisolona 10 mg/Kg/d y ácido acetil salicílico para manejo de MIS-C. Se brindó hidratación enérgica y alcalinización de orina para manejo de rabdomiólisis. Conclusión: Evolución favorable con alta luego de diez días. Existen pocos casos reportados de rabdomiólisis asociados a MIS-C, y ninguno con valores tan altos de CK. En base a las posibles complicaciones se sugiere realizar dosaje de CK de forma rutinaria en todos los pacientes con MIS-C.

Introduction: A case of severe rhabdomyolysis associated with multisystem inflammatory syndrome related to COVID-19 (MIS-C). Case of report: is presented in a one-year 10-month-old boy who presented digestive symptoms, myalgia, weakness, fever, and dark urine. COVID-19 IgM (-) IgG (+) serological test, COVID-19 PCR negative. Initial creatine kinase (CK) presented non-dosable values, with the highest reported level being 517,600 U/L. The creatinine value remained normal throughout the hospitalization. He received human immunoglobulin 2 g/Kg, Methylprednisolone 10 mg/Kg/d, and acetylsalicylic acid to manage MIS-C. Aggressive hydration and urine alkalinization were provided to manage rhabdomyolysis. Conclusion: Positive evolution with discharge after ten days. Few reported cases of rhabdomyolysis are associated with MIS-C and none with such high CK values. Based on the possible complications, performing CK dosing in all patients with MIS-C is suggested routinely.

Multi System Inflammatory Syndrome In Neonates (MIS-N): A Case Report

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during pregnancy may increase the risk of stillbirth, neonatal death, preterm birth, low birth weight, fetal distress, and neonatal asphyxia. Vertical transmission of SARS-CoV-2 is under investigation. Afew reports suggest the possibility of SARS-CoV-2 transmission from mothers to their neonates. The SARS-CoV-2 virus was reported as one of the rare causes of fetal inflammatory response syndrome (FIRS) and is associated with multisystem inflammatory syndrome in children (MIS-C).

Clinical Characteristics of Children With SARS-CoV-2 Infection During the Third Wave of the Pandemic: Single Center Experience

Objective: To determine the clinical presentation and outcome of children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the third wave of the pandemic in India. Method: A review of hospital records was done at a tertiary care hospital, for children seen between 1 and 25 January, 2022. Result: Out of total 112 SARS-CoV-2 positive patients, 17 were hospitalized and 95 were treated in the outpatient department. Among non-hospitalized children, fever was the commonest feature (72, 75.7%), followed by sneezing, and loss of appetite. The median (IQR) duration of symptoms was 2.5 (1.5) days. Among hospitalized children, 10 had co-morbidities and one-third required intensive care unit admission. MIS-C was diagnosed in four patients. Out of 4 mechanically ventilated patients, two had coronavirus disease (COVID) pneumonia. The mean (SD) length of hospital stay was 7.5 (2.5) days. One child with leukemia died during management. Conclusion: During the third wave of the pandemic, most children had symptomatic illnesses, but recovery was fast among non-hospitalized children.

Características clínicas de pacientes pediátricos con síndrome de dificultad respiratoria aguda asociado con COVID-19 / Clinical characteristics of pediatric patients with acute respiratory distress syndrome due to COVID-19

Resumen Introducción: Existen pocos reportes de síndrome de dificultad respiratoria aguda (SDRA) con COVID-19 en pacientes pediátricos. El objetivo de este estudio fue describir las características de los pacientes pediátricos críticamente enfermos con COVID-19, la frecuencia del SDRA, la mecánica ventilatoria y los resultados de la posición prona. Métodos: Se llevó a cabo un estudio retrospectivo y observacional de los pacientes ingresados del 1 de abril al 30 de septiembre de 2020. Resultados: Ingresaron 34 pacientes a la unidad de terapia intensiva pediátrica (UTIP) con prueba positiva para SARS-CoV-2. De ellos, 13 presentaron SDRA, 11 requirieron ventilación mecánica invasiva y siete fueron pronados como estrategia de oxigenación. Todos los pacientes clasificados como SDRA graves fueron pronados. La obesidad fue la comorbilidad más importante. Las complicaciones asociadas con SDRA fueron el síndrome inflamatorio multisistémico (p < 0.05) y la lesión renal aguda (p < 0.05). La procalcitonina fue mayor en los pacientes con SDRA, al igual que los días de estancia en la UTIP (p < 0.05). El éxito de la maniobra de pronación se alcanzó 8 horas después.Los resultados observados fueron los siguientes relación presión arterial de oxígeno/fracción inspirada de oxígeno 128 vs. 204, índice de oxigenación 8.9 vs. 5.9, distensibilidad pulmonar estática 0.54 vs. 0.70 ml/cmH2O/kg, y presión meseta 24 vs. 19 cmH2O (p < 0.05). El uso de narcóticos fue mayor en el grupo de SDRA más pronación que en los no pronados (124 vs. 27 h; p < 0.01). La mortalidad asociada con SARS-CoV-2 fue del 5.8%. Conclusiones: El SDRA se presentó en el 38.2% de los niños admitidos a UTIP, y con mayor frecuencia en los pacientes con obesidad. La maniobra de pronación aplicada en los casos severos, mejoró la oxigenación de la mécanica pulmonar. Ninguno de los pacientes falleció por SDRA.

Abstract Background: There are only a few reports of acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 in pediatrics. This study aimed to describe the characteristics of critically ill pediatric patients with COVID-19, the frequency of ARDS, ventilatory mechanics and results of prone position. Methods: We conducted a retrospective, observational study of patients admitted to the pediatric intensive care unit (PICU) between April 1 to September 30, 2020. Results: Thirty-four patients were admitted to pediatric intensive care unit, 31.7% were SARS-CoV-2 positive. 13 presented ARDS, 11 required invasive mechanical ventilation, and seven were pronated as an oxygenation strategy. All patients classified as severe ARDS were pronated. Obesity was the most important comorbidity. The complications associated with ARDS were multisystemic inflammatory syndrome (8 vs. 4; p < 0.05) and acute kidney injury (8 vs. 3; p < 0.05). Procalcitonin was higher in patients with ARDS, as were the days of stay in PICU (p < 0.05). The success of the pronation maneuver was achieved 8 hours later , with the following results: arterial oxygen partial pressure to fractional inspired oxygen ratio 128 vs. 204, oxygenation index 8.9 vs. 5.9, static lung compliance 0.54 vs. 0.70 ml/cmH2O/kg, plateau pressure 24 vs. 19 cmH2O (p < 0.05). The use of narcotics was higher in the group with ARDS plus pronation 124 vs. 27 hours in the non-pronated (p < 0.01). Mortality associated with SARS-CoV-2 was 5.8%. Conclusions: ARDS was presented in 38.2% of the children admitted to PICU and was more frequent in obese patients. Pronation, performed in severe cases, improved oxygenation and lung mechanics indexes. No patient died of ARDS.

Estudio multicéntrico de casos confirmados de COVID-19: datos preliminares de 2690 pacientes pediátricos en Argentina durante el primer año de la pandemia / A multicenter study of confirmed COVID-19 cases: preliminary data on 2690 pediatric patients in Argentina during the first year of the pandemic

Introducción. La evidencia actual indica que la gravedad de la enfermedad por el coronavirus 2019 (COVID-19, por su sigla en inglés) es menor en la población pediátrica, los datos locales aún son limitados. Objetivo: caracterizar los aspectos clínicos y epidemiológicos de la infección por COVID-19 en menores de 18 años en Argentina. Población y métodos. Estudio transversal, observacional y analítico de casos confirmados de COVID-19 entre 0 y 18 años asistidos entre marzo de 2020 y marzo de 2021 en 19 centros pediátricos de referencia de Argentina. Se realizó un análisis multivariado para identificar las variables predictoras de cuadros graves. Resultados. Se incluyeron 2690 casos de COVID-19: 77,7 % residentes del área metropolitana de Buenos Aires, 50,1 % de sexo masculino, mediana de edad de 5,6 años. El 90 % ocurrió entre las semanas epidemiológicas 20-47 del 2020; 60,4 % con antecedente de contacto con personas con COVID-19; y 96,6 % en el entorno familiar. El 51,4 % presentó síntomas respiratorios; 61,6 % síntomas generales; 18,8 % síntomas gastrointestinales; 17,1 % síntomas neurológicos; 7,2 % otros y 21,5 % fueron asintomáticos. El 59,4 % fue hospitalizado; 7,4 fueron graves o críticos. Se registraron 57 casos de síndrome inflamatorio multisistémico. El antecedente de asma, displasia broncopulmonar, cardiopatía congénita, desnutrición moderada a grave, obesidad, enfermedad neurológica crónica y/o edad menor de 6 meses resultaron predictores independientes de gravedad. Residir en barrios vulnerables resultó protector. Conclusiones. Más de la mitad de los casos refirieron antecedente de contacto con personas con COVID-19 en el entorno familiar. La hospitalización no respondió a criterios clínicos de gravedad. La gravedad se encuentra asociada a la existencia de ciertas comorbilidades.

Introduction. The current evidence indicates that the severity of the coronavirus disease 2019 (COVID-19) is lower in the pediatric population but local data are still limited. Objective: To characterize the clinical and epidemiological aspects of COVID-19 infection in patients younger than 18 years in Argentina. Population and methods. Cross-sectional, observational, and analytical study of confirmed COVID-19 patients aged 0-18 years seen between March 2020 and March 2021 at 19 referral children's hospitals of Argentina. A multivariate analysis was done to identify predictors of severe cases. Results. A total of 2690 COVID-19 cases were included: 77.7% lived in the Metropolitan Area of Buenos Aires; 50.1% were males; patients' median age was 5.6 years. Of them, 90% were seen during epidemiological weeks 20-47 of 2020; 60.4% had a history of contact with COVID-19 patients; and 96.6% in their family setting. Also, 51.4% had respiratory symptoms; 61.6%, general symptoms; 18.8%, gastrointestinal symptoms; 17.1%, neurological symptoms; 7.2%, other symptoms; and 21.5% were asymptomatic. In addition, 59.4% of patients were hospitalized and 7.4% had a severe or critical course. A total of 57 patients developed multisystem inflammatory syndrome. A history of asthma, bronchopulmonary dysplasia, congenital heart disease, moderate to severe malnutrition, obesity, chronic neurological disease and/or age younger than 6 months were independent predictors of severity.Livinginavulnerableneighborhoodwas a protective factor. Conclusions. More than half of cases referred a history of contact with COVID-19 patients in the family setting. Hospitalization was not based on clinical criteria of severity. Severity was associated with the presence of certain comorbidities

Síndrome inflamatorio multisistémico asociado a COVID-19

Introducción: En mayo de 2020 en Reino Unido y EE UU se documentaron casos de una enfermedad que compartía características clínicas y analíticas con la enfermedad de Kawasaki, la cual se asoció a una disregulación inmunitaria secundaria a una infección reciente por SARS-CoV-2. Objetivo: Comunicar las experiencias de la evolución y el tratamiento de una paciente con diagnóstico de esta nueva enfermedad. Presentación del caso: Adolescente de 17 años con antecedentes de haber padecido de COVID-19 seis semanas antes de su presentación en el hospital. Se recibe con lesiones mucocutáneas, polipnea, taquicardia, ictericia y astenia. Dos horas después de llegar a la unidad de cuidados intensivos comenzó con taquicardia ventricular sin pulsos, de la cual hizo dos eventos que requirieron reanimación cardiopulmonar avanzada. Fue necesario apoyo inotrópico por varios días debido a la afectación miocárdica. Después de 72 h con una fracción de eyección del ventrículo izquierdo por debajo de 35 %, comenzó a mejorar hasta la recuperación completa. Recibió tratamiento con metilprednisolona IV y con el péptido inmunoregulador cubano jusvinza. Conclusiones: El síndrome inflamatorio multisistémico asociado a COVID-19, presentado por primera vez en la provincia de Cienfuegos, es una afección nueva, que usualmente es grave y requiere cuidados intensivos debido a que produce disfunción orgánica, pero sobre todo afectación cardíaca. Tiene una presentación clínica similar a enfermedades más comunes, por lo que es fundamental estar alerta para un diagnóstico oportuno que garantice el éxito del tratamiento y evite la muerte.

Introduction: In May 2020, cases of a disease that shared clinical and analytical features with Kawasaki disease were documented in the United Kingdom and the United States, which were associated with immune dysregulation secondary to a recent SARS-CoV-2 infection. Objective: To communicate the experiences of the evolution and treatment of a patient diagnosed with this new disease. Case presentation: A 17-year-old teenager with a history of COVID-19 six weeks ago. He was admitted with mucocutaneous lesions, polypnea, tachycardia, jaundice and asthenia. Two hours after arriving at the intensive care unit, he presented pulseless ventricular tachycardia, of which he did two events that required advanced cardiopulmonary resuscitation. Inotropic support was required for several days due to myocardial involvement. After 72 hours with a left ventricular ejection fraction below 35%, he began to improve until complete recovery. He received treatment with IV methylprednisolone and the Cuban immunoregulatory peptide jusvinza. Conclusions: The multisystem inflammatory syndrome associated with COVID-19, presented for the first time in the province of Cienfuegos, is a new condition, which is usually serious and requires intensive care because it produces organic dysfunction, but above all cardiac involvement. It has a clinical presentation similar to more common diseases, so it is essential to be alert for a timely diagnosis that guarantees the success of treatment and prevents death.

Advances in diagnosis and treatment of multisystem inflammatory syndrome in children / 国际儿科学杂志

Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection may lead to multisystem inflammatory syndrome in children(MIS-C). MIS-C mostly occurs in older children and adolescents who have laboratory or epidemiological evidence of SARS-CoV-2 infection.The clinical manifestations include persistent fever, hypotension, elevated inflammation markers, and symptoms of multiple organ involvement, which is similar to Kawasaki disease.Once the disease occurs, it can progress rapidly and worsen in a short time, and most children require intensive care admission.Although the overall prognosis is good, some patients have adverse results such as death.We should strengthen the monitoring and management of suspected children and improve the level of diagnosis and treatment of the disease.

Asociación de comorbilidades con infección sintomática y síndrome inflamatorio multisistémico por SARS-CoV-2 en niños / Association of comorbidities and symptomatic infection and multisystemic inflammatory syndrome due to SARS-CoV-2 in children

INTRODUCCIÓN: En niños, la infección por el nuevo coronavirus (SARS-CoV-2) habitualmente cursa asintomática o con síntomas leves; sólo una proporción menor presenta síntomas graves o un conjunto de signos y síntomas postinfecciosos descritos como síndrome inflamatorio multisistémico pediátrico (SIMP). OBJETIVO: Describir la asociación de comorbilidades con la infección sintomática y SIMP por SARS-CoV-2 en niños. PACIENTES Y MÉTODOS: Estudio transversal analítico, se incluyeron pacientes pediátricos hospitalizados. Mediante reacción de la polimerasa en cadena y/o pruebas antigénicas se diagnosticó la infección activa y con la definición propuesta por la Organización Mundial de la Salud se identificaron pacientes con SIMP. RESULTADOS: Se estudiaron 375 pacientes, la mediana de edad fue de 3,8 años. El 47,7% (n: 179) presentó comorbilidades, siendo las más frecuentes: neoplasias sólidas y/o enfermedades hematológicas 17,1% (n: 64), obesidad 13,3% (n: 48) y neumopatías crónicas 9,3% (n: 35). Presentaron infección por SARS-CoV-2 el 16,5% (n: 62/375) y SIMP el 10,4% (n. 39/375). Los niños con obesidad mostraron mayor riesgo de infección sintomática (OR 2,21, IC 95% 1,05-4,6) y en aquellos con cáncer (OR 0,15, IC 95% 0,03-0,68) el riesgo de SIMP fue menor. CONCLUSIONES: La presencia de comorbilidades modifica el riesgo de infección por SARS-CoV-2 y SIMP.

BACKGROUND: In children, infection by the new coronavirus (SARS-CoV-2) usually occurs asymptomatic or with mild clinical data, only a minor proportion have severe symptoms or a set of post-infectious signs and symptoms described as Pediatric Inflammatory Multisystemic Syndrome (PIMS). AIM: To describe the association of comorbidities with symptomatic infection and PIMS due to SARS-CoV-2 in children. METHODS: Analytical cross-sectional study, pediatric patients hospitalized were included. Active infection was diagnosed by polymerase chain reaction and/or antigenic tests. Patients with PIMS were identified by the definition proposed by the World Health Organization. RESULTS: 375 patients were studied, the median age was 3.8 years. 47.7% (n: 179) had comorbidities, the most frequent were: solid neoplasms and/or hematological diseases 17.1% (n: 64), obesity 13.3% (n: 48) and chronic pneumopathies 9, 3% (n: 35). SARS-CoV-2 infection was present in 16.5% (n: 62/375) and PIMS in 10.4% (n. 39/375). Children with obesity showed a higher risk of infection (OR 2.21, 95% CI 1.05-4.6) and in those with cancer (OR 0.15, 95% CI 0.03-0.68) the PIMS risk was lower. CONCLUSIONS: The presence of comorbidities modifies the risk of infection by SARS-CoV-2 and PIMS.

Consenso sobre el tratamiento del síndrome inflamatorio multisistémico asociado a COVID-19 / Consensus on treatment of multisystemic inflammatory syndrome associated with COVID-19

La pandemia ocasionada por el nuevo coronavirus (SARS-CoV-2), declarada por la Organización Mundial de la Salud OMS) en marzo de 2020, afecta a un reducido número de pacientes pediátricos, quienes presentan, en su mayoría, compromiso respiratorio leve y evolución favorable. Sin embargo, en niños previamente sanos, comenzó a observarse un aumento de casos definidos como síndrome inflamatorio multisistémico (SIM-C) o similar a Kawasaki (Kawasaki-like) asociado a la enfermedad por el nuevo coronavirus (COVID-19) (KL-C) que evolucionan al shock y requieren internación en la unidad de cuidados intensivos.Los cuadros de SIM-C y los KL-C se caracterizan por fiebre, signos de inflamación, síntomas gastrointestinales y disfunción cardiovascular; las formas graves de presentación tienen mayor incidencia de hipotensión y/o shock. En el laboratorio se observan marcadores de inflamación, hipercoagulabilidad y daño miocárdico. El tratamiento farmacológico de primera línea consiste en la administración de inmunoglobulina por vía intravenosa más ácido acetilsalicílico por vía oral.Se recomienda un abordaje multidisciplinario para un diagnóstico certero y un tratamiento temprano y eficaz para disminuir la morbimortalidad.

The pandemic caused by the SARS-CoV-2 virus declared by the WHO in March 11th 2020, affects a small number of pediatric patients, who mostly present mild respiratory compromise and favorable evolution.However began to be observed in previously healthy children, an increase in cases defined as "Multisystemic Inflammatory Syndrome" (MIS-C) or "Kawasaki-like" post-COVID 19 (KL-C) that evolve to shock and require hospitalization in the Pediatric Intensive Care Unit.MIS-C and KL-C are characterized by fever; signs of inflammation, gastrointestinal symptoms, and cardiovascular dysfunction, associated with sever forms of presentation with higher incidence of hypotension and/or shock. In the laboratory, markers of inflammation, hypercoagulability and myocardial damage are observed. First-line drug treatment consists of intravenous immunoglobulin plus oral acetylsalicylic acid.A multidisciplinary approach is recommended for an accurate diagnosis and an early and effective treatment, in order to reduce morbidity and mortality.

Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: a multicenter, prospective cohort study

Abstract Objective To describe the clinical, laboratory, and radiological characteristics, as well as the outcomes of children with MIS-C. Method Multicenter, prospective cohort study, conducted in 17 pediatric intensive care units in five states in Brazil, from March to July 2020. Patients from 1 month to 19 years who met the MIS-C diagnostic criteria were included consecutively. Results Fifty-six patients were included, with the following conditions: Kawasaki-like disease (n = 26), incomplete Kawasaki disease (n = 16), acute cardiac dysfunction (n = 10), toxic shock syndrome (n = 3), and macrophage activation syndrome (n = 1). Median age was 6.2 years (IQR 2.4−10.3), 70% were boys, 59% were non-whites, 20% had comorbidities, 48% reported a contact with COVID-19 cases, and 55% had a recent SARS-CoV-2 infection confirmed by RT-PCR and/or serology. Gastrointestinal symptoms were present in 71%, shock symptoms in 59%, and severe respiratory symptoms in less than 20%. -Dimer was increased in 80% and cardiac dysfunction markers in more than 75%. Treatment included immunoglobulin (89%); corticosteroids, antibiotics, and enoxaparin in about 50%; and oseltamivir and antifungal therapy in less than 10%. Only 11% needed invasive mechanical ventilation, with a median duration of five days (IQR 5-6.5). The median length of PICU stay was six days (IQR 5-11), and one death occurred (1.8%). Conclusions Most characteristics of the present MIS-C patients were similar to that of other cohorts. The present results may contribute to a broader understanding of SARS-CoV-2 infection in children and its short-term consequences. Long-term multidisciplinary follow-up is needed, since it is not known whether these patients will have chronic cardiac impairment or other sequelae.

Síndrome inflamatória multissistêmica em crianças associada à infecção pelo coronavírus: relato de caso / Multisystem inflammatory syndrome in children associated with coronavirus infection: a case report

No dia 11 de março de 2020 a Organização Mundial da Saúde declarou pandemia pelo novo coronavírus, Sars-Cov-2. A doença, denominada COVID-19, expandiu-se de forma rápida e grave, gerando sérias preocupações mundiais. Estudos envolvendo a população pediátrica estão revelando o perfil de acometimento do coronavírus em crianças e, embora muitas delas apresentem casos de COVID-19 de forma assintomática, algumas desenvolvem casos graves da doença. Uma série de relatos de casos publicados recentemente, especialmente na Europa, Ásia, América do Norte e América Latina, descreveram uma forma mais grave pela infecção do Sars-Cov-2 em crianças: a síndrome inflamatória multissistêmica associada à COVID-19 na Criança (MIS-C). Acredita-se que uma reação hiperinflamatória causada por uma resposta imune inata desregulada seja a causa dos danos teciduais. No entanto, a fisiopatologia dessa síndrome ainda não está completamente elucidada. As manifestações clínicas dessa síndrome se assemelham a algumas doenças já conhecidas, como a Doença de Kawasaki e a Síndrome do Choque Tóxico, dentre outras. Dessa forma, os protocolos para diagnóstico e terapêutica a serem empregados na MIS-C estão sendo desenvolvidos com base naqueles já utilizados no manejo dessas duas enfermidades, e medicamentos como corticoides, anticoagulantes e antirretrovirais têm apresentado bons resultados. Ainda há muito a ser investigado em relação à MIS-C, mas já se faz presente a necessidade do acompanhamento ambulatorial após alta hospitalar a fim de prevenir e tratar as possíveis consequências dessa hiperinflamação.

On March 11, 2020 the World Health Organization declared a pandemic caused by the new coronavirus, SARS-CoV-2. The disease, named COVID-19, has expanded rapidly and severely, generating serious global concern. Studies involving the pediatric population are revealing the profile of coronavirus involvement in children, and although many children present as asymptomatic cases of COVID-19, some develop severe forms of the disease. A number of recently published case reports, especially from Europe, Asia, North America, and Latin America, have described a more severe form of Sars-Cov-2 infection in children: the multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C). A hyperinflammatory reaction caused by a dysregulated innate immune response is believed to be the cause of tissue damage. However, the pathophysiology of this syndrome is not yet fully elucidated. The clinical manifestations of this syndrome resemble those of some known diseases, such as Kawasaki disease and toxic shock syndrome, among others. Thus, the protocols for diagnosis and therapy to be employed in MIS-C are being developed based on those already used in the management of these two diseases, and drugs such as corticoids, anticoagulants, and antiretroviral drugs have shown good results. There is still much to be investigated regarding MIS-C, but outpatient follow-up after hospital discharge is required to prevent and treat the possible consequences of this hyperinflammation.

Síndrome inflamatorio multisistémico en niños, relacionado con COVID-19: actualización a propósito de la presentación de 2 pacientes críticos / Multisystem inflammatory syndrome in children related to COVID-19: An update regarding the presentation of two critically ill patients

El síndrome inflamatorio multisistémico en niños asociado con enfermedad por coronavirus 2019 se define por la presencia de fiebre persistente, inflamación y disfunción orgánica, con evidencia de infección pasada o reciente por coronavirus tipo 2 del síndrome respiratorio agudo grave, y exclusión de otra causa microbiana. Acarrea la superposición con otras enfermedades inflamatorias (enfermedad de Kawasaki y síndrome de shock tóxico) y comparte características con entidades que presentan hipercitocinemia (linfohistiocitosis hemofagocítica y síndrome de activación macrofágica). Se diferencia de estas y de la forma aguda grave de enfermedad por coronavirus 2019 en su presentación clínica y parámetros de laboratorio. Su evolución es potencialmente grave y puede presentar falla cardiovascular; la mortalidad es baja (del 2 %).Se realiza una actualización de este síndrome, y se describe la presentación de 2 casos clínicos con disfunción cardiovascular, que requirieron sostén vasoactivo y asistencia ventilatoria invasiva. El laboratorio sérico evidenció parámetros de inflamación. Ambos recibieron tratamiento con gammaglobulina endovenosa y corticoides sistémicos, con evolución favorable

Multisystem inflammatory syndrome in children related to COVID-19 is defined as the presence of persistent fever, inflammation, and organ dysfunction, with evidence of past or recent severe acute respiratory syndrome coronavirus 2 infection, and excluding other microbial causes. It overlaps with other inflammatory diseases (Kawasaki disease and toxic shock syndrome) and shares some features with hypercytokinemia conditions (hemophagocytic lymphohistiocytosis and macrophage activation syndrome). It differs from these and severe acute COVID-19 in its clinical presentation and laboratory parameters. It has a potentially severe course and may occur with cardiovascular failure; mortality is low (2 %).Here we provide an update on this syndrome and describe the presentation of two clinical cases with cardiovascular dysfunction who required vasoactive support and invasive ventilation. Serum lab tests showed inflammation parameters. Both patients were treated with intravenous immunoglobulin and systemic corticosteroids and had a favorable course

Síndrome inflamatória multissistêmica pediátrica (SIM-P) na Bahia, em 2020 / Multisystem inflammatory syndrome in children (MIS-C) in Bahia, in 2020 / Síndrome inflamatorio multisistémico pediátrico (SIM-P) en Bahía, 2020

A Síndrome Inflamatória Multissistêmica Pediátrica (SIM-P) é uma nova apresentação clínica em crianças e adolescentes, na faixa etária de zero a 19 anos, temporalmente associada à infecção pelo SAR-CoV-2. O objetivo deste estudo é analisar o perfil epidemiológico dos casos de SIM-P na Bahia. Trata-se de um estudo exploratório descritivo, com revisão de literatura, análise documental e das notificações de SIM-P realizadas no formulário on-line do REDCap, no período de 20 de julho a 4 de dezembro de 2020, considerando a orientação do Ministério da Saúde para a realização de busca ativa de casos desde 26 de fevereiro de 2020, data da confirmação do primeiro caso de Covid-19 no país. Na Bahia, nesse período, foram realizadas 66 notificações, com a confirmação de 42 casos, dos quais três evoluíram para óbito, 38 tiveram alta e um continua internado. As faixas etárias foram agrupadas em intervalos de cinco anos, sendo a faixa de 5 a 9 anos a que concentrou o maior número de casos (N = 20; 47,6%) e a faixa de 15 a 19 anos a que apresentou o menor número (N = 2; 4,8%). A média de idade coincidiu com a mediana, que foi de oito anos. Houve predomínio do sexo masculino, com 25 casos, representando 59,5%. Em relação à análise de ocorrência dos primeiros sintomas, o mês de julho registrou a maior concentração de casos no período estudado (28,6%). As informações obtidas por meio da vigilância da SIM-P são fundamentais para o conhecimento do perfil epidemiológico, podendo contribuir para o melhor manejo clínico dos casos.

Multisystem Inflammatory Syndrome in Children (MIS-C) is a new clinical presentation in children and adolescents aged zero to nineteen, temporarily associated with SARS-CoV-2 infection. This study aims at analyzing the epidemiological profile of MIS-C cases in the state of Bahia. This is an exploratory descriptive study, with a literature review, document analysis and MIS-C notifications made on the REDCap online form, from July 20 to December 4, 2020, considering the guidance of the Ministry of Health to conduct an active search for cases since February 26, 2020, date of confirmation of the first case of Covid-19 in the country. In the state, during this period, 66 notifications were made, with the confirmation of 42 cases, of which three evolved to death, 38 were discharged and one is still hospitalized. The age groups were grouped into five-year intervals, with the range of 5 to 9 years old having the highest number of cases (N = 20; 47.6%) and the range of 15 to 19 years old having the lowest number (N = 2; 4.8%). The mean age coincided with the median, which was 8 years. There was a predominance of boys, with 25 cases, representing 59.5%. Regarding the analysis of the occurrence of the first symptoms, July registered the highest concentration of cases (28.6%). The information obtained by the surveillance of MIS-C is fundamental for the knowledge of the epidemiological profile and may contribute to the better clinical management of cases.

El síndrome inflamatorio multisistémico pediátrico (SIM-P) es una nueva presentación clínica en niños y adolescentes de 0 a 19 años, temporalmente asociada a la infección por SARS-CoV-2. El objetivo de este estudio es analizar el perfil epidemiológico de los casos de SIM-P en Bahía. Este es un estudio exploratorio descriptivo, con revisión de literatura, análisis de documentos y notificaciones SIM-P realizadas en el formulario en línea de REDCap, del 20 de julio al 4 de diciembre de 2020, considerando la orientación del Ministerio de Salud para realizar una búsqueda activa de casos desde el 26 de febrero de 2020, fecha de confirmación del primer caso del covid-19 en el país. En Bahía, durante ese período, se realizaron 66 notificaciones, con la confirmación de 42 casos, de los cuales tres evolucionaron a muerte, 38 fueron dados de alta y uno aún se encuentra hospitalizado. Los grupos de edad se agruparon en intervalos de cinco años, con el rango de 5 a 9 años con el mayor número de casos (N = 20; 47,6%) y el rango de 15 a 19 años con el número más bajo (N = 2; 4,8%). La edad media coincidió con la mediana, que fue de 8 años. Predominó el sexo masculino, con 25 casos, representando el 59,5%. En cuanto al análisis de la ocurrencia de los primeros síntomas, el mes de julio registró la mayor concentración de casos en el período analizado (28,6%). La información obtenida por la vigilancia del SIM-P es fundamental para conocer el perfil epidemiológico, lo que puede contribuir al mejor manejo clínico de los casos.

Systemic inflammatory syndrome in children during COVID-19 pandemic in Ceará state, northeastern Brazil: an observational study

Abstract In this study, we report the occurrence of multisystemic inflammatory syndrome among 64 children (2 deaths) with recent severe acute respiratory syndrome-related coronavirus 2 (SARS-COV-2) infections in the northeast region of Brazil. The major clinical symptoms and signs reported were exanthema (60.9%), abdominal pain (56.3%), nausea and vomiting (46.9%), diarrhea (37.5%), and dyspnea (37.5%). Laboratory findings revealed that the levels of C-reactive protein (75.0%), hemoglobin (51.6%), D-dimer (48.4%), lymphocytes (43.8%), LDH (45.3%), AST (42.2%), ALT (51.6%), and ferritin (48.4%) were above the reference values for a given age and gender. The clinical findings were similar to those observed in Kawasaki disease, although it represents a separate entity, emphasizing the need for proactive surveillance and early treatment.

Persistent symptoms and decreased health-related quality of life after symptomatic pediatric COVID-19: A prospective study in a Latin American tertiary hospital

OBJECTIVES: To prospectively evaluate demographic, anthropometric and health-related quality of life (HRQoL) in pediatric patients with laboratory-confirmed coronavirus disease 2019 (COVID-19) METHODS: This was a longitudinal observational study of surviving pediatric post-COVID-19 patients (n=53) and pediatric subjects without laboratory-confirmed COVID-19 included as controls (n=52) was performed. RESULTS: The median duration between COVID-19 diagnosis (n=53) and follow-up was 4.4 months (0.8-10.7). Twenty-three of 53 (43%) patients reported at least one persistent symptom at the longitudinal follow-up visit and 12/53 (23%) had long COVID-19, with at least one symptom lasting for >12 weeks. The most frequently reported symptoms at the longitudinal follow-up visit were headache (19%), severe recurrent headache (9%), tiredness (9%), dyspnea (8%), and concentration difficulty (4%). At the longitudinal follow-up visit, the frequencies of anemia (11% versus 0%, p=0.030), lymphopenia (42% versus 18%, p=0.020), C-reactive protein level of >30 mg/L (35% versus 0%, p=0.0001), and D-dimer level of >1000 ng/mL (43% versus 6%, p=0.0004) significantly reduced compared with baseline values. Chest X-ray abnormalities (11% versus 2%, p=0.178) and cardiac alterations on echocardiogram (33% versus 22%, p=0.462) were similar at both visits. Comparison of characteristic data between patients with COVID-19 at the longitudinal follow-up visit and controls showed similar age (p=0.962), proportion of male sex (p=0.907), ethnicity (p=0.566), family minimum monthly wage (p=0.664), body mass index (p=0.601), and pediatric pre-existing chronic conditions (p=1.000). The Pediatric Quality of Live Inventory 4.0 scores, median physical score (69 [0-100] versus 81 [34-100], p=0.012), and school score (60 [15-100] versus 70 [15-95], p=0.028) were significantly lower in pediatric patients with COVID-19 at the longitudinal follow-up visit than in controls. CONCLUSIONS: Pediatric patients with COVID-19 showed a longitudinal impact on HRQoL parameters, particularly in physical/school domains, reinforcing the need for a prospective multidisciplinary approach for these patients. These data highlight the importance of closer monitoring of children and adolescents by the clinical team after COVID-19.

Children's Multisystem inflammatory syndrome with myopathy

Abstract This report describes a case of multisystem inflammatory syndrome in a child that evolved with a pattern of toxic shock syndrome with coronary artery ectasia and neurological involvement, documented by magnetic resonance imaging, with changes in the corpus callosum and myopathy in the pelvic girdle and paravertebral musculature.

Severe acute respiratory syndrome-coronavirus-2 infection: A review of the clinical-pathological correlations of coronavirus disease-19 in children

@#The coronavirus disease-19 (COVID-19) has become a global pandemic of acute respiratory disease in just less than a year by the middle of 2020. This disease caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has resulted in significant mortality especially among the older age population and those with health co-morbidities. In contrast, children are relatively spared of this potentially ravaging disease that culminates in the acute respiratory distress syndrome, multi-organ failure and death. SARS-CoV-2 infection induces exuberant release of pro-inflammatory mediators, causing a “cytokine storm” and hypercoagulable states that underlie these complications. The SARS-CoV-2 infection median incubation is 5.1 days, with most developing symptoms by 11.5 days. It is highly infectious, spreading via the horizontal mode of transmission, but there is yet very limited evidence of vertical transmission to the newborn infant occurring either transplacentally or through breastfeeding. This said, various immune factors during childhood may modulate the expression of COVID-19, with the multisystem inflammatory syndrome in children (MIS-C) at the severe end of the disease spectrum. This article gives an overview of the SARS-CoV-2 infection, clinical presentation and laboratory tests of COVID-19 and correlating with the current understanding of the pathological basis of this disease in the paediatric population.

Update on the diagnosis and management of COVID-19 in pediatric patients

Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), became a pandemic in March 2020, affecting millions of people worldwide. However, COVID-19 in pediatric patients represents 1-5% of all cases, and the risk for developing severe disease and critical illness is much lower in children with COVID-19 than in adults. Multisystem inflammatory syndrome in children (MIS-C), a possible complication of COVID-19, has been described as a hyperinflammatory condition with multiorgan involvement similar to that in Kawasaki disease or toxic shock syndrome in children with evidence of SARS-CoV-2 infection. This review presents an update on the diagnostic methods for COVID-19, including reverse-transcriptase polymerase chain reaction (RT-PCR) tests, serology tests, and imaging, and summarizes the current recommendations for the management of the disease. Particular emphasis is placed on respiratory support, which includes noninvasive ventilation and invasive mechanical ventilation strategies according to lung compliance and pattern of lung injury. Pharmacological treatment, including pathogen-targeted drugs and host-directed therapies, has been addressed. The diagnostic criteria and management of MIS-C are also summarized.